What is the 13F Pro Quality Score for SLNO?

13F Pro ranks SOLENO THERAPEUTICS INC (SLNO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SLNO's current score at https://13fpro.ai/research/SLNO (free sign-up required for the full ranking).

Which hedge funds own the most SLNO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SLNO include FMR, WELLINGTON MANAGEMENT GROUP LLP, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SLNO as soon as new 13F filings post.

Where does 13F Pro source SLNO data?

All SOLENO THERAPEUTICS INC fundamentals and ownership data come directly from SEC EDGAR. SOLENO THERAPEUTICS INC files with the SEC under CIK 1484565. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SLNO in?

SOLENO THERAPEUTICS INC (SLNO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SLNO research updated on 13F Pro?

SLNO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SOLENO THERAPEUTICS INC(SLNO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1484565 SLNO stock profile & AI dashboard →

13F Pro Quality Score

46.3/100

Rank #1,672 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

97.5/100

Profitability

30.0/100

Balance Sheet

48.7/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

51.5/100

Revenue Scale

30.0/100

Dilution Risk

7.7/100

SLNO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SOLENO THERAPEUTICS INC (SLNO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SLNO at 46.3/100 on a 32-signal composite quality model, placing it at rank #1,672 of 2,879 stocks — the bottom half of the AI-ranked universe. SLNO scores in the top quartile across revenue growth (97.5). Areas of concern include profitability (30.0) and free cash flow (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SOLENO THERAPEUTICS INC reports quarterly revenue of $94.6M, net income of $31.4M, an operating margin of 33.1%. Top institutional holders of SLNO by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, BlackRock,, based on the most recent SEC filings. SLNO trades on the Nasdaq exchange and files with the SEC under CIK 1484565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLNO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SOLENO THERAPEUTICS INC directly from SEC EDGAR. SOLENO THERAPEUTICS INC's 13F Pro composite quality score has ranged between 29 and 46 since 2026, currently 46.3 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about SOLENO THERAPEUTICS INC

Quirks, history, and lore behind SLNO — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · listed on Nasdaq · headquartered in San Diego, California · focused on rare disease drug development.
2
The Numbers
A classic pre-revenue clinical-stage biotech — minimal commercial income, spending heavily on R&D with a market cap in the hundreds of millions of dollars.
3
The History
The company's lead program targets a genetic disorder causing severe obesity and behavioral problems, a condition so rare it affects only a small fraction of the population.
4
The Secret
Its lead drug candidate, a vasopressin V1b receptor antagonist, aims to address the relentless hunger and hyperphagia that make the underlying syndrome so difficult to manage.
5
The Lore
The condition it targets — Prader-Willi syndrome — is characterized by an insatiable appetite, and patients and families have had almost no approved pharmacological options for decades.
6
The Giveaway
Its drug diazoxide choline (DCCR) generated significant clinical trial buzz in the Prader-Willi community — this San Diego rare-disease biotech's ticker rhymes with a certain volcanic island chain.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$94.6M

Net Income

Q1 2026

$31.4M

Free Cash Flow

Q1 2026

$25.9M

Operating Margin

Q1 2026

33.1%

ROIC

Q1 2026

5.7%

D/E Ratio

Q1 2026

0.10

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2024

FY21 —FY22 —FY23 —FY24 —

Net Income

-351.0% YoY

$-175.8MFY 2024

FY21 $-30.9MFY22 $-24.1MFY23 $-39.0MFY24 $-175.8M

Operating Income

-353.5% YoY

$-187.7MFY 2024

FY21 $-31.5MFY22 $-24.4MFY23 $-41.4MFY24 $-187.7M

EPS (Diluted)

-85.6% YoY

$-4.38FY 2024

FY21 $-2.90FY22 $-1.44FY23 $-2.36FY24 $-4.38

Total Assets

+83.2% YoY

$331.0MFY 2024

FY21 $35.6MFY22 $26.5MFY23 $180.7MFY24 $331.0M

Total Debt

$49.8MFY 2024

FY21 —FY22 —FY23 —FY24 $49.8M

Op. Cash Flow

-177.0% YoY

$-69.1MFY 2024

FY21 $-27.8MFY22 $-20.8MFY23 $-24.9MFY24 $-69.1M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2016
Revenue	—	—	—	—	—	$1.5M
Net Income	$-175.8M -351.0%	$-39.0M -62.0%	$-24.1M +22.1%	$-30.9M -0.4%	$-30.8M -155.1%	$-12.1M
Operating Income	$-187.7M -353.5%	$-41.4M -69.6%	$-24.4M +22.6%	$-31.5M -34.2%	$-23.5M -182.1%	$-8.3M
EPS (Diluted)	$-4.38 -85.6%	$-2.36 -64.5%	$-1.44 +50.6%	$-2.90	—	—
Total Assets	$331.0M +83.2%	$180.7M +581.9%	$26.5M -25.5%	$35.6M -6.9%	$38.2M +585.9%	$5.6M
Total Debt	$49.8M	—	—	—	—	—
Operating Cash Flow	$-69.1M -177.0%	$-24.9M -20.0%	$-20.8M +25.2%	$-27.8M -59.8%	$-17.4M -28.7%	$-13.5M

AI Insight: SLNO Financial Trends

SLNO flipped to profitability in Q4 2025 after five consecutive loss quarters, with Q1 2026 sustaining $95M revenue and $31M net income.

• Revenue emerged from zero to $95M in Q1 2026, signaling a commercial launch inflection after quarters of pure pre-revenue burn.

• Net income swung from -$77M in Q3 2024 to +$31M in Q1 2026 — a ~$108M turnaround in five quarters.

• Operating cash flow turned positive at $49M in Q4 2025 and held at $26M in Q1 2026, ending a streak of cash-burn quarters.

• Equity expanded sharply from $232M in Q1 2025 to $496M in Q1 2026, strengthening the balance sheet materially.

⚠ Two differing Q4 2025 data rows ($92M vs $66M revenue; $43M vs $26M net income) suggest restatement or reporting inconsistency — warrants scrutiny.

⚠ Operating cash flow decelerated from $49M in Q4 2025 to $26M in Q1 2026 despite higher revenue — watch working capital dynamics.

⚠ Total debt held flat at $50M since Q4 2024; monitor whether revenue growth triggers debt paydown or additional leverage.

AI Insight: SLNO Ratio Trends

SLNO has swung from deeply negative returns to 20%+ ROA and ROE in Q1 2026, marking a dramatic profitability inflection.

• ROE surged from -115.8% in Q3 2024 to +25.3% in Q1 2026, a near-140pp turnaround over five quarters.

• ROA improved from -67.7% in Q4 2024 to +20.6% in Q1 2026, reflecting asset productivity gains.

• Leverage (D/E) declined from 0.21 in Q1–Q2 2025 to 0.10 in Q1 2026, strengthening the balance sheet.

• Q1 2026 operating margin of 33.1% and net margin of 33.2% confirm sustained, not one-off, profitability.

⚠ Two distinct Q4 2025 rows show diverging margins (43.1% vs 33.5% OpMargin) — data inconsistency warrants clarification.

⚠ OpMargin edged down from 33.5% to 33.1% Q4 2025→Q1 2026; monitor for further compression as the business scales.

⚠ TTM ROIC of 15.8% trails the Q1 2026 quarterly ROIC of 22.9%, suggesting profitability is still early-stage and lumpy.

Get alerted when SLNO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SOLENO THERAPEUTICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SLNO

FMR LLC
$193.8M5,788,410 sh
WELLINGTON MANAGEMENT GROUP LLP
$148.2M4,426,781 sh
BlackRock, Inc.
$125.3M3,742,774 sh
STATE STREET CORP
$89.8M2,680,802 sh
Avoro Capital Advisors LLC
$77.0M2,300,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$72.1M2,153,218 sh
Nantahala Capital Management, LLC
$58.4M1,744,124 sh
Polar Capital Holdings Plc
$56.9M1,698,855 sh
Khrom Capital Management LLC
$50.6M1,511,481 sh
GEODE CAPITAL MANAGEMENT, LLC
$41.4M1,237,550 sh

Fund	Value	Shares
FMR LLC	$193.8M	5,788,410
WELLINGTON MANAGEMENT GROUP LLP	$148.2M	4,426,781
BlackRock, Inc.	$125.3M	3,742,774
STATE STREET CORP	$89.8M	2,680,802
Avoro Capital Advisors LLC	$77.0M	2,300,000
VANGUARD CAPITAL MANAGEMENT LLC	$72.1M	2,153,218
Nantahala Capital Management, LLC	$58.4M	1,744,124
Polar Capital Holdings Plc	$56.9M	1,698,855
Khrom Capital Management LLC	$50.6M	1,511,481
GEODE CAPITAL MANAGEMENT, LLC	$41.4M	1,237,550

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SLNO on your watchlist

Track score changes the day SOLENO THERAPEUTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SLNO a good stock to buy?

13F Pro's AI-powered analysis of SOLENO THERAPEUTICS INC (SLNO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SLNO are available on the SLNO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SLNO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SLNO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SOLENO THERAPEUTICS INC's investment landscape.